Serum efficacy biomarkers for oncology

Biomarkers in Medicine

Volumn 3, Issue 1, 2009, Pages 47-54

  Linder, Stig ^a   Alaiya, Ayodele ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CARCINOEMBRYONIC ANTIGEN; CASPASE; CELL DNA; CISPLATIN; CYTOCHROME C; CYTOKERATIN; CYTOTOXIC AGENT; DOCETAXEL; FAS LIGAND; NAVELBINE; PHARMACOLOGICAL BIOMARKER; PLATINUM COMPLEX; PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL 2; TAMOXIFEN; UVOMORULIN;

ADJUVANT THERAPY; ADVANCED CANCER; ANALYTIC METHOD; APOPTOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; BREAST CANCER; CANCER CELL; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESEARCH; DRUG RESPONSE; ENZYME DEGRADATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; NUCLEOSOME; ONCOLOGY; OVARY CANCER; PATIENT CARE; PATIENT MONITORING; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY; SOLID TUMOR; TREATMENT OUTCOME;

EID: 68049091812     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/17520363.3.1.47     Document Type: Review

References (80)

1. Jaffe CC: Measures of response: RECIST, WHO, and new alternatives. J. Clin. Oncol. 24, 3245-3251 (2006).
2. Srivastava S, Srivastava RG: Proteomics in the forefront of cancer biomarker discovery. J. Proteome Res. 4, 1098-1103 (2005).
3. Finek J, Holubec L Jr, Topolcan O et al.: Clinical relevance of tumor markers for the control of chemotherapy. Anticancer Res. 25, 1655-1658 (2005).
4. Sorbye H, Dahl O: Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to oxaliplatin combination chemotherapy: implications for tumor marker monitoring and guidelines. J. Clin. Oncol. 21, 4466-4467 (2003).
5. Aquino A, Prete SP, Guadagni F et al.: Effect of 5-xuorouracil on carcinoembryonic antigen expression and shedding at clonal level in colon cancer cells. Anticancer Res. 20, 3475-3484 (2000).
6. Vicini FA, Vargas C, Abner A, Kestin L, Horwitz E, Martinez A: Limitations in the use of serum prostate specific antigen levels to monitor patients after treatment for prostate cancer. J. Urol. 173, 1456-1462 (2005).
7. Locker GY, Hamilton S, Harris J et al.: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J. Clin. Oncol. 24, 5313-5327 (2006).
8. Holdenrieder S, Stieber P: Apoptotic markers in cancer. Clin. Biochem. 37, 605-617 (2004).
9. Linder S, Havelka AM, Ueno T, Shoshan MC: Determining tumor apoptosis and necrosis in patient serum using cytokeratin 18 as a biomarker. Cancer Lett. 214, 1-9 (2004).
10. Brown JM, Attardi LD: The role of apoptosis in cancer development and treatment response. Nat. Rev. Cancer 5, 231-237 (2005).
11. Berndtsson M, Hagg M, Panaretakis T, Havelka AM, Shoshan MC, Linder S: Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA. Int. J. Cancer 120, 175-180 (2007).
12. Tanaka M, Suda T, Haze K et al.: Fas ligand in human serum. Nat. Med. 2, 317-322 (1996).
13. Midis GP, Shen Y, Owen-Schaub LB: Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. Cancer Res. 56, 3870-3874 (1996).
14. Mizutani Y, Hongo F, Sato N, Ogawa O, Yoshida O, Miki T: Significance of serum soluble Fas ligand in patients with bladder carcinoma. Cancer 92, 287-293 (2001).
15. Jodo S, Kobayashi S, Nakajima Y et al.: Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma. Clin. Exp. Immunol. 112, 166-171 (1998).
16. Kondera-Anasz Z, Mielczarek-Palacz A, Sikora J: Soluble Fas receptor and soluble Fas ligand in the serum of women with uterine tumors. Apoptosis 10, 1143-1149 (2005).
17. Konno R, Takano T, Sato S, Yajima A: Serum soluble fas level as a prognostic factor in patients with gynecological malignancies. Clin. Cancer Res. 6, 3576-3580 (2000).
18. Niitsu N, Sasaki K, Umeda M: A high serum soluble Fas/APO-1 level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma. Leukemia 13, 1434-1440 (1999).
19. Munker R, Younes A, Cabanillas F, Andreeff M: Soluble CD95 in the serum of patients with low and intermediate grade malignant lymphomas: absence of prognostic correlations. Leuk. Lymphoma 27, 517-521 (1997).
20. Nonomura N, Nishimura K, Ono Y et al.: Soluble Fas in serum from patients with renal cell carcinoma. Urology 55, 151-155 (2000).
21. Bewick M, Conlon M, Parissenti AM et al.: Soluble Fas (CD95) is a prognostic factor in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous stem cell transplantation. J. Hematother. Stem Cell Res. 10, 759-768 (2001).
22. Chaudhry P, Srinivasan R, Patel FD, Gopalan S, Majumdar S: Serum soluble Fas levels and prediction of response to platinum-based chemotherapy in epithelial ovarian cancer. Int. J. Cancer 122, 1716-1721 (2008).
23. Mizutani Y, Matsubara H, Yamamoto K et al.: Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma. Cancer 101, 1794-1802 (2004).
24. Tas F, Duranyildiz D, Argon A et al.: Serum bcl-2 and survivin levels in melanoma. Melanoma Res. 14, 543-546 (2004).
25. Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E: The value of serum bcl-2 levels in advanced epithelial ovarian cancer. Med. Oncol. 23, 213-217 (2006).
26. Mouawad R, Antoine EC, Gil-Delgado M, Khayat D, Soubrane C: Serum caspase-1 levels in metastatic melanoma patients: relationship with tumour burden and non-response to biochemotherapy. Melanoma Res. 12, 343-348 (2002).
27. Renz A, Berdel WE, Kreuter M, Belka C, Schulze-Osthoff K, Los M: Rapid extracellular release of cytochrome c is specific for apoptosis and marks cell death in vivo. Blood 98, 1542-1548 (2001).
28. Barczyk K, Kreuter M, Pryjma J et al.: Serum cytochrome c indicates in vivo apoptosis and can serve as a prognostic marker during cancer therapy. Int. J. Cancer 116, 167-173 (2005).
29. Björklund B, Björklund V: Antigenicity of pooled human malignant and normal tissues by cyto-immunological technique: presence of an insoluble, heat-labile tumor antigen. Int. Arch. Allergy 10, 153-184 (1957).
30. Björklund B: Tissue polypeptide antigen (TPA): biology, biochemistry, improved assay methodology, clinical significance in cancer and other conditions, and future outlook. Antibiot. Chemother. 22, 16-31 (1978).
31. Ku NO, Liao J, Omary MB: Apoptosis generates stable fragments of human type I keratins. J. Biol. Chem. 272, 33197-33203 (1997).
32. Caulin C, Salvesen GS, Oshima RG: Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis. J. Cell. Biol. 138, 1379-1394 (1997).
33. Dohmoto K, Hojo S, Fujita J et al.: The role of caspase 3 in producing cytokeratin 19 fragment (CYFRA 21-21) in human lung cancer cell lines. Int. J. Cancer 91, 468-473 (2001).
34. Sheard MA, Vojtesek B, Simickova M, Valik D: Release of cytokeratin-18 and -19 fragments (TPS and CYFRA 21-21) into the extracellular space during apoptosis. J. Cell. Biochem. 85, 670-677 (2002).
35. Kramer G, Erdal H, Mertens HJ et al.: Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res. 64, 1751-1756 (2004).
36. Leers MP, Kölgen W, Björklund V et al.: Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J. Pathol. 187, 567-572 (1999).
37. Ueno T, Toi M, Bivén K, Bando H, Ogawa T, Linder S: Measurement of an apoptosis product in the sera of breast cancer patients. Eur. J. Cancer 39, 769-774 (2003).
38. Bivén K, Erdal H, Hägg M et al.: A novel assay for discovery and characterization of pro-apoptotic drugs and for monitoring apoptosis in patient sera. Apoptosis 8, 263-268 (2003).
39. Kramer G, Schwarz S, Hägg M, Havelka AM, Linder S: Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles. Br. J. Cancer 94, 1592-1598 (2006).
40. Demiray M, Ulukaya EE, Arslan M et al.: Response to neoadjuvant chemotherapy in breast cancer could be predictable by measuring a novel serum apoptosis product, caspase-cleaved cytokeratin 18: a prospective pilot study. Cancer Invest. 24, 669-676 (2006).
41. Pichon MF, Labroquere M, Rezai K, Lokiec F: Variations of soluble fas and cytokeratin 18-Asp 396 neoepitope in different cancers during chemotherapy. Anticancer Res. 26, 2387-2392 (2006).
42. Cummings J, Ward TH, LaCasse E et al.: Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br. J. Cancer 92, 532-538 (2005).
43. Cummings J, Ranson M, Lacasse E et al.: Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br. J. Cancer 95, 42-48 (2006).
44. Cummings J, Ranson M, Butt F, Moore D, Dive C: Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma. Cancer Chemother. Pharmacol. 60, 921-924 (2007).
45. Olofsson MH, Ueno T, Pan Y et al.: Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy. Clin. Cancer Res. 13, 3198-3206 (2007).
46. Greystoke A, Cummings J, Ward T et al.: Optimisation of circulating biomarkers of cell death for routine clinical use. Ann. Oncol. 19, 990-995 (2008).
47. Petrylak DP, Tangen CM, Hussain MH et al.: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351, 1513-1520 (2004).
48. Stieber P, Hasholzner U, Bodenmuller H et al.: CYFRA 21-21. A new marker in lung cancer. Cancer 72, 707-713 (1993).
49. Giovanella L, Ceriani L, Ghelfo A, Maffioli M: Circulating cytokeratin 19 fragments in patients with benign nodules and carcinomas of the thyroid gland. Int. J. Biol. Markers 23, 54-57 (2008).
50. Andreadis C, Touloupidis S, Galaktidou G, Kortsaris AH, Boutis A, Mouratidou D: Serum CYFRA 21-21 in patients with invasive bladder cancer and its relevance as a tumor marker during chemotherapy. J. Urol. 174, 1771-1775; discussion 1775-1776 (2005).
51. Nisman B, Biran H, Heching N et al.: Prognostic role of serum cytokeratin 19 fragments in advanced non-small-cell lung cancer: association of marker changes after two chemotherapy cycles with different measures of clinical response and survival. Br. J. Cancer 98, 77-79 (2008).
52. Ishii T, Bandoh S, Fujita J et al.: Full-length cytokeratin 8 is released and circulates in patients with non-small cell lung cancer. Tumour Biol. 29, 57-62 (2008).
53. Steinhusen U, Weiske J, Badock V, Tauber R, Bommert K, Huber O: Cleavage and shedding of E-cadherin after induction of apoptosis. J. Biol. Chem. 276, 4972-4980 (2001).
54. Nolen BM, Marks JR, Ta'san S et al.: Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer. Breast Cancer Res. 10, R45 (2008).
55. Anderson NL, Anderson NG: The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics 1, 845-867 (2002).
56. Tirumalai RS, Chan KC, Prieto DA, Issaq HJ, Conrads TP, Veenstra TD: Characterisation of the low molecular weight human serum proteome. Mol. Cell. Proteomics 2, 1096-1103 (2003).
57. Petricoin EF, Liotta LA: Proteomic approaches in cancer risk and response assessment. Trends Mol. Med. 10, 59-64 (2004).
58. Mandel P, Metais P: Les acid nucleius du plasma sanguin chez l'homme. Biologie 3, 241 (1947).
59. Anker P, Mulcahy H, Chen XQ, Stroun M: Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev. 18, 65-73 (1999).
60. Lichtenstein AV, Melkonyan HS, Tomei LD, Umansky SR: Circulating nucleic acids and apoptosis. Ann. NY Acad. Sci. 945, 239-249 (2001).
61. Stroun M, Maurice P, Vasioukhin V et al.: The origin and mechanism of circulating DNA. Ann. NY Acad. Sci. 906, 161-168 (2000).
62. Fournie GJ, Courtin JP, Laval F et al.: Plasma DNA as a marker of cancerous cell death. Investigations in patients suffering from lung cancer and in nude mice bearing human tumours. Cancer Lett. 91, 221-227 (1995).
63. Kamat AA, Bischoff FZ, Dang D et al.: Circulating cell-free DNA: a novel biomarker for response to therapy in ovarian carcinoma. Cancer Biol. Ther. 5, 1369-1374 (2006).
64. Wang BG, Huang HY, Chen YC et al.: Increased plasma DNA integrity in cancer patients. Cancer Res. 63, 3966-3968 (2003).
65. Ellinger J, Bastian PJ, Ellinger N et al.: Apoptotic DNA fragments in serum of patients with muscle invasive bladder cancer: a prognostic entity. Cancer Lett. 264, 274-280 (2008).
66. Ellinger J, Bastian, PJ, Haan KI et al.: Noncancerous PTGS2 DNA fragments of apoptotic origin in sera of prostate cancer patients qualify as diagnostic and prognostic indicators. Int. J. Cancer 122, 138-143 (2008).
67. Shao ZM, Nguyen M: Tumor-specific DNA in plasma of breast cancer patients. Anticancer Drugs 13, 353-357 (2002).
68. Chang HW, Lee SM, Goodman SN et al.: Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer. J. Natl Cancer Inst. 94, 1697-1703 (2002).
69. Wong IH, Lo YM, Johnson PJ: Epigenetic tumor markers in plasma and serum: biology and applications to molecular diagnosis and disease monitoring. Ann. NY Acad. Sci. 945, 36-50 (2001).
70. Herman JG: Circulating methylated DNA. Ann. NY Acad. Sci. 1022, 33-39 (2004).
71. Fiegl H, Millinger S, Mueller-Holzner E et al.: Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res. 65, 1141-1145 (2003).
72. Wong IH, Zhang J, Lai PB, Lau WY, Lo YM: Quantitative analysis of tumor-derived methylated p16INK4a sequences in plasma, serum, and blood cells of hepatocellular carcinoma patients. Clin. Cancer Res. 9, 1047-1052 (2005).
73. Hu XC, Wong IH, Chow LW: Tumor-derived aberrant methylation in plasma of invasive ductal breast cancer patients: clinical implications. Oncol. Rep. 10, 1811-1815 (2003).
74. Wyllie AH: Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 284, 555-556 (1980).
75. Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A, Nagata S: A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 391, 43-50 (1998).
76. Holdenrieder S, Stieber P, Forg T et al.: Apoptosis in serum of patients with solid tumours. Anticancer Res. 19, 2721-2724 (1999).
77. Trejo-Becerril C, Pérez-Cárdenas E, Treviño-Cuevas H et al.: Circulating nucleosomes and response to chemotherapy: an in vitro, in vivo and clinical study on cervical cancer patients. Int. J. Cancer 104, 663-668 (2003).
78. Holdenrieder S, Stieber P, von Pawel J et al.: Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer. Clin. Cancer Res. 10, 5981-5987 (2004).
79. Holdenrieder S, Stieber P: Therapy control in oncology by circulating nucleosomes. Ann. NY Acad. Sci. 1022, 211-216 (2004).
80. Holdenrieder S, Stieber P, Von Pawel J et al.: Early and specific prediction of the therapeutic efficacy in non-small cell lung cancer patients by nucleosomal DNA and cytokeratin-19 fragments. Ann. NY Acad. Sci. 1075, 244-257 (2006).